{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:21:28Z","timestamp":1791994888138,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.cct.2020.105938","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T12:03:05Z","timestamp":1579694585000},"page":"105938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31\/ACTG A5349 phase 3 clinical trial"],"prefix":"10.1016","volume":"90","author":[{"given":"Susan E.","family":"Dorman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina V.","family":"Kurbatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan V.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Bozeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok-Chiu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jean","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney V.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phan","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Heilig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Lessem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Metchock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Miro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Viet","family":"Nhung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April C.","family":"Pettit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P.J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Podany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Purfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Robergeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadzanai","family":"Samaneka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Sizemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Chaisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2020.105938_bb0005","series-title":"Geneva, Switzerland: World Health Organization; 2018. Report No.: 978\u201392\u20134-156564-6","author":"World Health Organization. Global tuberculosis report","year":"2018"},{"key":"10.1016\/j.cct.2020.105938_bb0010","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw566","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0015","series-title":"Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care, 2017 Update","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.cct.2020.105938_bb0020","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0025","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1093\/cid\/cir184","article-title":"Why do we use 600 mg of rifampicin in tuberculosis treatment?","volume":"52","author":"van Ingen","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0030","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1164\/rccm.201207-1210OC","article-title":"Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model","volume":"187","author":"de Steenwinkel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2020.105938_bb0035","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fmicb.2015.00641","article-title":"High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo","volume":"6","author":"Hu","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.cct.2020.105938_bb0040","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2020.105938_bb0045","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1128\/AAC.00912-12","article-title":"Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis","volume":"56","author":"Rosenthal","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2020.105938_bb0050","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/AAC.01474-06","article-title":"Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears","volume":"51","author":"Diacon","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2020.105938_bb0055","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/cid\/ciy026","article-title":"The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis","volume":"67","author":"Svensson","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0060","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jac\/46.4.571","article-title":"Comparison of the in vitro activities of rifapentine and rifampicin against mycobacterium tuberculosis complex","volume":"46","author":"Bemer-Melchior","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cct.2020.105938_bb0065","first-page":"528","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial","volume":"360","author":"Benator","year":"2002","journal-title":"Lancet (British Edition)"},{"key":"10.1016\/j.cct.2020.105938_bb0070","first-page":"1843","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid","volume":"353","author":"Vernon","year":"1999","journal-title":"Tuberculosis Trials Consortium. Lancet (British Edition)"},{"key":"10.1016\/j.cct.2020.105938_bb0075","unstructured":"Pritin Package Insert.2018 Accessed 1 January 2020 at http:\/\/products.sanofi.us\/priftin\/Priftin.pdf"},{"key":"10.1016\/j.cct.2020.105938_bb0080","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.200807-1029OC","article-title":"Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?","volume":"178","author":"Rosenthal","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2020.105938_bb0085","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cct.2020.105938_bb0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial","volume":"191","author":"Dorman","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2020.105938_bb0095","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials","volume":"102","author":"Savic","year":"2017","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.cct.2020.105938_bb0100","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/AAC.42.8.2066","article-title":"In vitro and in vivo activities of moxifloxacin and clinafloxacin against mycobacterium tuberculosis","volume":"42","author":"Ji","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2020.105938_bb0105","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1128\/AAC.00105-15","article-title":"Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2020.105938_bb0110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/rccm.200603-360OC","article-title":"Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis","volume":"174","author":"Burman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2020.105938_bb0115","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial","volume":"373","author":"Conde","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2020.105938_bb0120","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.105938_bb0125","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/AAC.05208-11","article-title":"Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions","volume":"56","author":"Kjellsson","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2020.105938_bb0130","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1021\/ac1029049","article-title":"High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions","volume":"83","author":"Prideaux","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cct.2020.105938_bb0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijid.2017.05.003","article-title":"Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis","volume":"60","author":"Xu","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tube.2015.02.037","article-title":"Fluoroquinolones for the treatment of tuberculosis in children","volume":"95","author":"Thee","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.cct.2020.105938_bb0145","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","article-title":"Population-based resistance of mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","volume":"16","author":"Zignol","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0150","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1164\/rccm.201103-0536OC","article-title":"A multisite assessment of the quantitative capabilities of the Xpert MTB\/RIF assay","volume":"184","author":"Blakemore","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2020.105938_bb0155","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa0907847","article-title":"Rapid molecular detection of tuberculosis and rifampin resistance","volume":"363","author":"Boehme","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.105938_bb0160","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/00006454-199910000-00009","article-title":"Rifapentine pharmacokinetics in adolescents","volume":"18","author":"Marshall","year":"1999","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.cct.2020.105938_bb0165","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.105938_bb0170","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/thx.2003.019224","article-title":"Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection","volume":"59","author":"Breen","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.cct.2020.105938_bb0175","first-page":"1282","article-title":"Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis","volume":"11","author":"Burman","year":"2007","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0180","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.105938_bb0185","year":"2019"},{"key":"10.1016\/j.cct.2020.105938_bb0190","series-title":"Efavirenz Pharmacokinetics in HIV\/TB Coinfected Persons Initiating ART while Receiving High Dose Rifapentine. 20th International Workshop on Clinical Pharmacology of HIV","author":"SE","year":"2019"},{"key":"10.1016\/j.cct.2020.105938_bb0195","series-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"For the AIDS clinical trials group & tuberculosis trials consortium A5349 \/ study 31 team. Efavirenz pharmacokinetics in HIV\/TB Coinfected persons receiving Rifapentine","author":"Podany","year":"2018"},{"key":"10.1016\/j.cct.2020.105938_bb0200","series-title":"Communications in Statistics - Theory and Methods Communications in Statistics - Theory and Methods","first-page":"2017","article-title":"Some restricted randomization rules in sequential designs","volume":"12","author":"Soares","year":"1983"},{"key":"10.1016\/j.cct.2020.105938_bb0205","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0924-8579(94)90054-X","article-title":"Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals","volume":"3","author":"Chan","year":"1994","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.cct.2020.105938_bb0210","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/infdis\/jis461","article-title":"Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium","volume":"206","author":"Dorman","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0215","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1128\/AAC.00345-10","article-title":"Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers","volume":"54","author":"Zvada","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2020.105938_bb0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1378\/chest.115.1.12","article-title":"Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids","volume":"115","author":"Peloquin","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.cct.2020.105938_bb0225","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0962-8479(95)90551-0","article-title":"Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide","volume":"76","author":"Zent","year":"1995","journal-title":"Tuber. Lung Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0230","first-page":"241","article-title":"Timing of relapse in short-course chemotherapy trials for tuberculosis","volume":"14","author":"Nunn","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0235","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.105938_bb0240","series-title":"A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline plus PA-824 plus Linezolid in Subjects with Drug Resistant Pulmonary Tuberculosis. NCT02333799","year":"2019"},{"key":"10.1016\/j.cct.2020.105938_bb0245","series-title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients. NCT03338621","year":"2019"},{"key":"10.1016\/j.cct.2020.105938_bb0250","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.105938_bb0255","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.105938_bb0260","series-title":"The Common Terminology Criteria for Adverse Events version 4.03 published on June 14","year":"2010"},{"key":"10.1016\/j.cct.2020.105938_bb0265","first-page":"471","article-title":"Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second east African\/British Medical Research Council study","volume":"114","author":"East African\/British Medical Research Council","year":"1976","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0270","first-page":"3","article-title":"Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis","volume":"116","author":"East African\/British Medical Research Council","year":"1977","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0275","first-page":"165","article-title":"Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African\/British medical research councils study","volume":"123","author":"East African\/British Medical Research Councils Study","year":"1981","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0280","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0041-3879(86)90027-9","article-title":"Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and central African\/British Medical Research Council fifth collaborative study","volume":"67","author":"East and Central Africa\/British Medical Research Council","year":"1986","journal-title":"Tubercle"},{"key":"10.1016\/j.cct.2020.105938_bb0285","series-title":"Singapore Tuberculosis Service\/British Medical Research Council","first-page":"779","article-title":"Singapore Tuberculosis Service\/British Medical Research Council. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis","volume":"133","year":"1986"},{"key":"10.1016\/j.cct.2020.105938_bb0290","series-title":"Developing Drugs for Treatment","author":"Guidance for Industry Pulmonary Tuberculosis","year":"2013"},{"key":"10.1016\/j.cct.2020.105938_bb0295","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1472-9792(08)70039-8","article-title":"Design issues in pivotal drug trials for drug sensitive tuberculosis (TB)","volume":"88","author":"Nunn","year":"2008","journal-title":"Tuberculosis Tuberculosis"},{"key":"10.1016\/j.cct.2020.105938_bb0300","unstructured":"The Consortium for TB Biomarkers (CTB2) Biorepository, Accessed 11 July, 2019, at https:\/\/www.tbbiorepository.org\/."},{"key":"10.1016\/j.cct.2020.105938_bb0305","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1164\/rccm.201105-0827WS","article-title":"CDC\/NIH workshop. Tuberculosis biomarker and surrogate endpoint research roadmap","volume":"184","author":"Nahid","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2020.105938_bb0310","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/infdis\/jiw364","article-title":"Adaptation of mycobacterium tuberculosis to impaired host immunity in HIV-infected patients","volume":"214","author":"Walter","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0315","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jiv149","article-title":"Transcriptional adaptation of drug-tolerant mycobacterium tuberculosis during treatment of human tuberculosis","volume":"212","author":"Walter","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2020.105938_bb0320","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1715849","article-title":"Bacterial factors that predict relapse after tuberculosis therapy","volume":"379","author":"Colangeli","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.cct.2020.105938_bb0325","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2020.105938_bb0330","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.cct.2020.105938_bb0335","series-title":"Clinical Data Interchange Standards Consortium (CDISC) Clinical Data Acquisition Standards Harmonization (CDASH)","year":"2019"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420300161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420300161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:47:27Z","timestamp":1761554847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714420300161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":67,"alternative-id":["S1551714420300161"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2020.105938","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31\/ACTG A5349 phase 3 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2020.105938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105938"}}